Cargando…

KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma

We reported that histone H3 lysine (K) 4 methyltransferase, KMT2D, serves as a potent tumor-suppressor in melanoma, which was identified via in vivo epigenome-focused RNA interference (RNAi) screen. KMT2D-deficient tumors show substantial reprogramming of key metabolic pathways including glycolysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Murugesan, Navya, Maitituoheti, Mayinuer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632269/
https://www.ncbi.nlm.nih.gov/pubmed/34859145
http://dx.doi.org/10.1080/23723556.2021.1984827